Regulatory T Cells in Severe Drug Eruptions

ISSN: 1875-631X (Online)
ISSN: 1573-3955 (Print)


Volume 10, 2 Issues, 2014


Download PDF Flyer




Current Immunology Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Cecil Czerkinsky
Institut de Pharmacologie Moleculaire et Cellulaire
UMR 7275 CNRS-INSERM-UNISA
660 Route des Lucioles
Valbonne, 06560
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Regulatory T Cells in Severe Drug Eruptions

Author(s): Tetsuo Shiohara, Ryo Takahashi, Yukiko Ushigome and Yoko Kano

Affiliation: Department of Dermatology, Kyorin University School of Medicine, Japan.

Abstract

Regulatory T cells (Tregs) are essential for limiting immunopathology and maintaining immune homeostasis. They represent a major barrier to aberrant and excessive immune responses to pathogens and allergens in infectious and allergic disease, respectively. In this review, we describe our current understanding of the immunopathogenic mechanism behind protection against the development and exacerbation of severe drug eruptions, with special emphasis on regulatory T cells (Tregs). In this regard, our previous study demonstrated that the timing of the dysfunction of Tregs could determine the pathological phenotype and sequelae of severe drug eruptions. We also discuss the factors that abrogate Treg function and demonstrate that Mycoplasma pneumoniae is the only pathogen shown to cause a persistent loss of Treg function long after clinical resolution. A loss of Treg function observed at the different stages of severe drug eruptions would be a driving force in the subsequent development of autoimmune disease as long-term sequelae of severe drug eruptions.


Purchase Online Rights and Permissions

  
  



Article Details

Volume: 10
First Page: 1
Page Count: 1
DOI: 10.2174/1573395510666140616234723
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science